Table 3.
Baseline variables as predictors of 5-year peritoneal dialysis outcomes.
| Study Variables | Time until Event (Month) HR (95% CI), p Value |
||
|---|---|---|---|
| PD Failure | MACE | ||
| Anthropometric and Clinical data |
Women | ns | ns |
| Age (years old) | p = 0.08 | 1.044 (1.012–1.077), p = 0.04 | |
| Diabetes mellitus | ns | 3.717 (1.732–7.978), p = 0.01 | |
| Arterial hypertension | ns | ns | |
| Coronary ischemic disease | ns | 10.063 (4.239–23.894), p = 0.001 | |
| Cerebrovascular disease | ns | 4.206 (1.409–12.582), p = 0.27 | |
| Cardiac failure | ns | p = 0.059 | |
| Peripheral arterial disease | 2.432 (1.066–5.552), p = 0.035 | 8.875 (3.890, 20.248), p = 0.001 | |
| GFRr (mL/min/1.73 m2) | ns | p = 0.110 | |
| Residual Diuresis (mL) | ns | ns | |
| PD and Therapeutics Prescription |
Icodextrin | p = 0.099 | ns |
| Use of amino acid solution | ns | ns | |
| Glucose applied | ns | ns | |
| Spironolactone | ns | ns | |
| Beta-blockers | ns | 3.518 (1.579–7.838), p = 0.001 | |
| Calcium channels blockers | 2.88 (1.139–7.236), p = 0.017 | ns | |
| Vitamin D analogues | ns | ns | |
| Non-calcium Phosphate binders | ns | ns | |
| Vitamin D3 supplements | ns | ns | |
| Cinacalcet | ns | ns | |
| Antiplatelet therapy | ns | 12.153 (4.982–29.745), p = 0.001 | |
| Statins | ns | ns | |
| Erythropoietin/darbepoetin | ns | ns | |
| PD-related parameters, Frailty | Peritoneal transport (High) | ns | ns |
| CA 125 (UI/L) | ns | ns | |
| nPCR (g/Kg/day) | ns | 0.093 (0.011–0.802), p = 0.024 | |
| Kt/V | p = 0.078 | 0.475 (0.260–0.869), p = 0.013 | |
| Frail | p = 0.093 | p = 0.073 | |
| Score de Edmonton | p = 0.150 | p = 0.051 | |
| Membrane Fibrosis and Serum biomarkers |
α-Klotho (pg/mL) | ns | p = 0.055 |
| Galectin-3 (ng/mL) | 1.271 (0.988–1.635), p = 0.042 | ns | |
| FGF21(pg/mL) | p = 0.146 | ns | |
| FGF23 (pg/mL) | ns | ns | |
| TWEAK (pg/mL) | p = 0.118 | ns | |
| TNF-α (pg/mL) | p = 0.087 | ns | |
| hs-CRP (μg/mL) | ns | ns | |
| Peritoneal membrane fibrosis | ns | 4.181 (1.905–9.175), p = 0.001 | |
| STM | ns | 1.009 (1.003–1.014), p = 0.001 | |
| α-Klotho < 742 pg/mL | ns | p = 0.055 | |
Data are present as hazard ratio (95% CI). PD—peritoneal dialysis; n—number of individuals; ns—non-significant; nPCR—normalized protein catabolic rate; Kt/V—Dialysis efficacy index; rGFR—residual glomerular filtration rate; CA125—cancer antigen 125; FGF21—Fibroblast growth factor 21; FGF23—Fibroblast growth factor 23 c-terminal; TWEAK—Tumor necrosis factor-like weak inducer of apoptosis; TNFα—Tumor necrosis factor α; hs-CRP—ultra-sensitive C-reactive protein; STM—submesothelial compact zone thickness.